The Respiratory Syncytial Virus Hospitalization Surveillance Network (RSV-NET) is a network that conducts active, population-based surveillance for laboratory-confirmed RSV-associated hospitalizations in children younger than 18 years of age and adults. The network currently includes 58 counties in 12 states, and data are collected and reported during the October 1-April 30 season each year. In some years, additional months of data are collected. In adults, RSV hospitalization tracking began in the 2016–2017 season. In children less than 18 years of age, surveillance began in the 2018–19 season. Because the surveillance areas and age groups included in surveillance have changed over time, trends should be interpreted with caution. Hospitalization data are preliminary and subject to change as more data become available. In particular, case counts and rates for recent hospitalizations are subject to lag. Lag for RSV-NET case identification and reporting might increase around holidays or during periods of increased hospitalization utilization. As data are received each week, prior case counts and rates are updated accordingly.
For more information about RSV-NET, please see https://www.cdc.gov/rsv/research/rsv-net.html.

The Respiratory Syncytial Virus Hospitalization Surveillance Network (RSV-NET) is a network that conducts active, population-based surveillance for laboratory-confirmed RSV-associated hospitalizations in children younger than 18 years of age and adults. The network currently includes 58 counties in 12 states, and data are collected and reported during the October 1-April 30 season each year. In some years, additional months of data are collected. In adults, RSV hospitalization tracking began in the 2016–2017 season. In children less than 18 years of age, surveillance began in the 2018–19 season. Because the surveillance areas and age groups included in surveillance have changed over time, trends should be interpreted with caution. Hospitalization data are preliminary and subject to change as more data become available. In particular, case counts and rates for recent hospitalizations are subject to lag. Lag for RSV-NET case identification and reporting might increase around holidays or during periods of increased hospitalization utilization. As data are received each week, prior case counts and rates are updated accordingly.
For more information about RSV-NET, please see https://www.cdc.gov/rsv/research/rsv-net.html.

More than 450 public health, clinical, and commercial laboratories located throughout the United States voluntarily participate in surveillance for respiratory syncytial virus (RSV) through CDC's National Respiratory and Enteric Virus Surveillance System (NREVSS) (https://www.cdc.gov/surveillance/nrevss/labs/index.html). The data contain weekly, aggregate counts of RSV tests performed and RSV detections as reported to NREVSS since April 11, 2020.

NREVSS data are reported weekly at the national and 10 HHS regional levels (https://www.hhs.gov/about/agencies/iea/regional-offices/index.html). The presented data are RSV Nucleic Acid Amplification Test (NAAT) results, which include reverse transcription-polymerase chain reaction (RT-PCR) tests. These data exclude antigen, antibody, and at-home test results. Less than 5% of RSV tests reported to NREVSS are from antigen tests. All data are provisional and subject to change. Reporting is less complete for the most recent weeks, but relatively complete (>90%) for the period up to 2 weeks earlier.

Percent positivity is a surveillance metric used to monitor RSV activity over time and by geographic area. Participating laboratories send weekly reports of the total number of RSV tests performed that week, and the number of those tests that were positive. In the table and upon hovering on the map, the total test counts reflect the latest data reported to NREVSS and may differ from data presented by public health jurisdictions. Public health jurisdictions may have additional data not reported to NREVSS and may use a different reporting cadence. The RSV trend graphs display the weekly average percent of tests positive for RSV among all the tests performed. Each point on the regional table displays the average number of RSV tests that were performed, and the average percent of those that were positive during a 3-week period (i.e., the specified week, and the weeks immediately preceding and following it). This is also known as a centered, 3-week moving average. The RSV detections displayed are the 5-week moving average (average of the 4 previous and current weeks) in accordance with the recommendations for assessing RSV trends by detections (https://academic.oup.com/jid/article/216/3/345/3860464).

NREVSS strives to present precise estimates of respiratory viral trends and minimize reporting burden for participating laboratories. However, there are several limitations to this surveillance system. NREVSS is a laboratory-based surveillance system that does not have patient-specific data; multiple tests from a single patient may be included. In addition, NREVSS does not collect demographic or clinical data (i.e., hospitalizations or deaths). Testing practices may vary regionally, and the number of participating laboratories may change from year to year. Laboratories from all 50 states report data weekly, but reporting is voluntary and may not be representative of local RSV activity. The data do not include all test results within a jurisdiction and therefore do not reflect all RSV NAATs administered regionally or nationally. Participating laboratories vary in size, testing capabilities, and areas and populations served. Geographic results from clinical laboratories are based on testing location and laboratories may test samples from across one or more states. For more information on NREVSS and RSV surveillance please visit: https://www.cdc.gov/surveillance/nrevss.

Approximately 600 public health and clinical laboratories located throughout the United States, participate in surveillance for respiratory syncytial virus (RSV) through CDC's National Respiratory and Enteric Virus Surveillance System (NREVSS). The dataset contains a weekly summary of the total RSV tests and RSV detections reported to NREVSS. These data are reported on a voluntary basis. Clinical laboratories do not report demographic data through NREVSS. Testing practices and the number of participating laboratories may change from year to year. Results can be changed two years after the initial reporting week. However, discrepancies may be noted and updated at the discretion of the data stewards and key stakeholders.

Data are collected from collaborating university and community hospital laboratories, select states and county public health laboratories, and commercial laboratories. This information is submitted and updated on a weekly basis.

While NREVSS strives to present the most precise national, regional and state respiratory viral trends with the least amount of burden possible for participating laboratories, there are a number of inherent limitations to this surveillance system.

NREVSS does not collect patient-data or demographic information. Multiple samples may be collected from a single patient, so NREVSS results do not necessarily reflect the number of patients tested nor does it reflect hospitalizations or deaths related to a particular virus.

Participating laboratories vary in size, testing capabilities, and areas served. Some institutions may receive and test samples from sites across a given state or even from multiple states. Without direct knowledge of the population base, NREVSS cannot be used to determine the prevalence or incidence of infection.

For more information on RSV surveillance and research please visit: https://www.cdc.gov/surveillance/nrevss and https://www.cdc.gov/rsv/research/us-surveillance.html

Weekly RSV Vaccination Coverage, Pregnant Persons 18-49 Years Old

• RSV vaccination coverage among pregnant persons is assessed through the Vaccine Safety Datalink*

• Data on RSV vaccinations among pregnant persons was available starting September 22, 2023, and includes doses received starting September 24, 2023.

Weekly Cumulative RSV Vaccination Coverage, by Race and Ethnicity, Medicare Fee-For-Service Beneficiaries aged 65 years

• Estimated COVID-19 vaccination coverage among Medicare fee-for-service beneficiaries >65 years is assessed using data files from the Medicare Fee-For-Service (FFS) administrative claims data managed by the Centers for Medicare & Medicaid Services (CMS).

• Starting in July 2023, the CDC recommended the RSV vaccine to protect against serious illness from RSV. (https://www.cdc.gov/respiratory-viruses/whats-new/rsv-update-2023-09-22.html

Weekly Intent for Vaccination and Cumulative Percentage of Adults 60 Years and Older Vaccinated with RSV Vaccine.

• RSV vaccination coverage among adults ages 60 years and older is assessed through the National Immunization Survey-Adult COVID Module providing weekly RSV vaccination coverage estimates. (https://www.cdc.gov/vaccines/imz-managers/nis/about.html)

• The CDC recommended the RSV vaccine for adults ages 60 years and older in July 2023. (https://www.cdc.gov/respiratory-viruses/whats-new/rsv-update-2023-09-22.html)

Weekly RSV Vaccination Coverage of Adults 60 Years and Older by Jurisdiction

• RSV vaccination coverage among adults 60 years and older is assessed through the National Immunization Survey-Adult COVID Module providing weekly RSV vaccination coverage estimates. (https://www.cdc.gov/vaccines/imz-managers/nis/about.html)

• The CDC recommended the RSV vaccine for adults 60 years and older in July 2023. (https://www.cdc.gov/respiratory-viruses/whats-new/rsv-update-2023-09-22.html)

Weekly RSV Vaccination Coverage of Adults 60 Years and Older by Demographic Characteristics

• RSV vaccination coverage among adults 60 years and older is assessed through the National Immunization Survey-Adult COVID Module providing weekly RSV vaccination coverage estimates. (https://www.cdc.gov/vaccines/imz-managers/nis/about.html)

• The CDC recommended the RSV vaccine for adults 60 years and older in July 2023. (https://www.cdc.gov/respiratory-viruses/whats-new/rsv-update-2023-09-22.html)

Weekly RSV Vaccination Coverage of Adults 60 Years and Older by Jurisdiction

• RSV vaccination coverage among adults 60 years and older is assessed through the National Immunization Survey-Adult COVID Module, providing weekly RSV vaccination coverage estimates. (https://www.cdc.gov/vaccines/imz-managers/nis/about.html)

• The CDC recommended the RSV vaccine for adults 60 years and older in July 2023. (https://www.cdc.gov/respiratory-viruses/whats-new/rsv-update-2023-09-22.html)